An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

You may be eligible if

• Inclusion:
• 1. Received prior treatment with NKTR-102
• 2. Free of disease progression since receiving NKTR-102
• 3. Adequate bone marrow and organ function
• 4. Treatment with NKTR-102 in the extension study to begin within 8 weeks after receipt of their of last dose of NKTR-102
• 5. Agree to use adequate contraception
• Exclusion:
• 1. Treatment with other anti-cancer therapy between the last dose of NKTR-102 in the prior study and before first dose of NKTR-102 in the extension study
• 2. A toxicity that requires a 3rd dose reduction after taking NKTR-102 or are scheduled to receive a dose \< 70 mg/m2 upon entry into this study
• 3. Pregnancy or lactation